Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | AURKA | O14965 | 4/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | IKBKB | O14920 | 2/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | PRKCG | P05129 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | LYN | P07948 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4470730 | 0.93 | SMN1; SMN2 (0.61) | SMN1; SMN2AURKAAURKBPRKCDNPC1 | |
| SCHEMBL27946092 | 0.77 | AURKA (0.51) | AURKAAURKBPRKCDNPC1MAPT | |
| SCHEMBL16353932 | 0.75 | SMN1; SMN2 (0.83) | SMN1; SMN2NPC1MAPTRAB9AHPGD | |
| SCHEMBL13755324 | 0.74 | AURKA (0.51) | AURKAAURKBPRKCDNPC1MAPT | |
| SCHEMBL4474314 | 0.73 | VSIR (0.60) | SMN1; SMN2AURKAAURKBPRKCDNPC1 | |
| SCHEMBL25879066 | 0.71 | GSK3A (0.57) | AURKAAURKBPRKCDNPC1MAPT | |
| SCHEMBL5962070 | 0.71 | AURKA (0.59) | AURKAAURKBPRKCDNPC1MAPT | |
| SCHEMBL7668890 | 0.70 | CXCR4 (0.49) | AURKAAURKBNPC1RAB9A | |
| SCHEMBL29484634 | 0.68 | AURKA (0.59) | AURKAAURKBPRKCDNPC1MAPT | |
| SCHEMBL670431 | 0.68 | KDM4E (0.62) | AURKAAURKBPRKCDNPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579344-B2 | Pyrimidine derivatives possessing cell-cycle inhibitors activity | ASTRAZENECA AB (SE) | 2009-08-25 | — | — | US | disclosed |
| US-20060229329-A1 | Pyrimidine derivatives possessing cell-cycle inhibitors activity | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229329-A1 | Pyrimidine derivatives possessing cell-cycle inhibitors activity | TYMP, CCNI, MKI67 | SMN1; SMN2 2402/4885AURKA 305/4885AURKB 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.